Cargando…
Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
OBJECTIVE: To evaluate the safety and efficacy of ospemifene for the treatment of moderate to severe vaginal dryness in postmenopausal women with vulvovaginal atrophy (VVA). METHODS: This 12-week, multicenter, double-blind phase 3 study randomized postmenopausal women (aged 40-80 years) with VVA and...
Autores principales: | Archer, David F., Goldstein, Steven R., Simon, James A., Waldbaum, Arthur S., Sussman, Steven A., Altomare, Corrado, Zhu, Julie, Yoshida, Yuki, Schaffer, Sam, Soulban, Graziella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott-Raven Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553508/ https://www.ncbi.nlm.nih.gov/pubmed/30694917 http://dx.doi.org/10.1097/GME.0000000000001292 |
Ejemplares similares
-
Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019) -
Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
por: Simon, James A., et al.
Publicado: (2018) -
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014) -
Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016) -
Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020)